Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $6,078 - $6,796
-105 Reduced 18.75%
455 $26,000
Q2 2023

Jul 24, 2023

SELL
$63.71 - $70.74 $3,631 - $4,032
-57 Reduced 9.24%
560 $35,000
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $51,713 - $58,655
-787 Reduced 56.05%
617 $42,000
Q4 2022

May 09, 2023

SELL
$68.48 - $81.09 $139,288 - $164,937
-2,034 Reduced 59.16%
1,404 $101,000
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $16 - $9,681
-126 Reduced 3.54%
3,438 $247,000
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $99,489 - $109,572
1,370 Added 62.44%
3,564 $274,000
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $67,259 - $80,649
1,094 Added 99.45%
2,194 $161,000
Q4 2021

Feb 15, 2022

BUY
$53.63 - $62.52 $17,966 - $20,944
335 Added 43.79%
1,100 $69,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $45,265 - $53,022
765 New
765 $46,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $122,891 - $133,828
-1,985 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $12,639 - $14,215
213 Added 12.02%
1,985 $126,000
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $29,736 - $33,696
-515 Reduced 22.52%
1,772 $110,000
Q3 2020

Nov 10, 2020

SELL
$57.43 - $63.64 $35,434 - $39,265
-617 Reduced 21.25%
2,287 $138,000
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $329,851 - $385,629
-6,017 Reduced 67.45%
2,904 $171,000
Q1 2020

May 12, 2020

BUY
$46.4 - $67.43 $381,732 - $554,746
8,227 Added 1185.45%
8,921 $497,000
Q4 2019

Feb 11, 2020

SELL
$49.21 - $64.19 $1.14 Million - $1.48 Million
-23,075 Reduced 97.08%
694 $45,000
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $209,188 - $248,022
-4,891 Reduced 17.07%
23,769 $1.19 Million
Q2 2019

Aug 06, 2019

BUY
$44.62 - $49.34 $1.28 Million - $1.41 Million
28,660 New
28,660 $1.3 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Altshuler Shaham LTD Portfolio

Follow Altshuler Shaham LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

News

Stay updated on Altshuler Shaham LTD with notifications on news.